SCHEMBL21333242

SCHEMBL21333242

CCOC(=O)c1nc(C)n(Cc2ccc(F)cc2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
KDM4E B2RXH2 3/20 0.52
PKM P14618 1/20 0.52
ALDH1A1 P00352 4/20 0.50
HTT P42858 2/20 0.50
POLB P06746 1/20 0.50
LMNA P02545 6/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ELANE P08246 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
TSHR P16473 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15987314 0.86 TSHR (0.61) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL21333538 0.83 PTGS2 (0.44) MAPTKDM4EALDH1A1HTTPOLB
SCHEMBL21332975 0.83 POLB (0.44) MAPTKDM4EALDH1A1HTTPOLB
SCHEMBL21333137 0.80 LMNA (0.41) MAPTKDM4EPKMALDH1A1HTT
SCHEMBL21332900 0.79 MAPT (0.39) MAPTKDM4EPKMALDH1A1HTT
SCHEMBL15937175 0.76 CYP19A1 (0.57) MAPTKDM4EPKMPOLBLMNA
SCHEMBL7878712 0.76 TSHR (0.58) MAPTKDM4EALDH1A1POLBLMNA
SCHEMBL2886654 0.74 MAPT (0.43) MAPTKDM4EPKMALDH1A1HTT
SCHEMBL18003522 0.74 GABRA2 (0.62) MAPTKDM4EPKMALDH1A1LMNA
SCHEMBL19224648 0.74 LMNA (0.53) MAPTKDM4EPKMALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 MAPT 4749/4885KDM4E 2671/4885PKM 1741/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 MAPT 4749/4885KDM4E 2671/4885PKM 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.